Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy.
Marius E MayerhoeferAnton StaudenherzBarbara KiesewetterMichael WeberIngrid Simonitsch-KluppPeter GibbsWerner DolakJulius LukasMarkus RadererPublished in: Molecular imaging and biology (2020)
TLG may improve early risk stratification of MALT lymphoma patients treated with CD20-antibody-based immunotherapy.